ESR1 and breast cancer: Unlike other studies illustrating that BRCA1 mutant tumors feature higher grade, invasive borders and higher proliferation indices; while BRCA2 mutation carriers are more likely to present with ER positive tumors and increased risk of contralateral breast cancer [29,44], however these differences were not noted in the current study.